The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Incresync



Takeda Pharma A/SEU/1/13/842/01-09

Main Information

Trade NameIncresync
Active SubstancesAlogliptin (as benzoate)
Pioglitazone (as hydrochloride)
Dosage FormFilm-coated tablet
Licence HolderTakeda Pharma A/S
Licence NumberEU/1/13/842/01-09

Group Information

ATC CodeA10BD Combinations of oral blood glucose lowering drugs
A10BD09 pioglitazone and alogliptin

Status

License statusAuthorised
Licence Issued19/09/2013
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back